OncoFusion Therapeutics Reacquires Rights to BET Bromodomain Inhibitors

ANN ARBOR, MI — (January 15, 2016) – OncoFusion Therapeutics, Inc. announced today that it has reached an agreement with Medivation, Inc. to reacquire the rights to certain compounds targeting Bromodomain and Extra-Terminal (BET) proteins identified and developed under a research and license agreement announced between the parties in April 2014.   OncoFusion plans to… Read More

Dr. Chinnaiyan in Wall Street Journal

The Prostate Cancer Quandary- Scientists may soon be able to answer the agonizing question facing men with prostate cancer: Does their cancer need treatment or can it be left alone? Some 218,000 American men will be diagnosed with prostate cancer this year. An estimated 85% of those tumors will grow so slowly that they will never… Read More

Wang and Sorensen in NY Times

For the first time ever, three pharmaceutical companies are poised to test whether new drugs can work against a wide range of cancers independently of where they originated — breast, prostate, liver, lung. The drugs go after an aberration involving a cancer gene fundamental to tumor growth. Many scientists see this as the beginning of a new… Read More

Dr. Chinnaiyan in NY Times

Dr. Arul Chinnaiyan stared at a printout of gene sequences from a man with cancer, a subject in one of his studies. There, along with the man’s cancer genes, was something unexpected — genes of the virus that causes AIDS. Barbara B. Biesecker took part in a case in which researchers decided to breach an agreement with… Read More